Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT06667414 · View on ClinicalTrials.gov ↗

Study Summary

For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.

Conditions Studied

Study Locations (20)

California

  • University of California San Diego — La Jolla
  • University of California Davis Medical System — Sacramento

New South Wales

  • Calvary Health Care Bethlehem — Caulfield South
  • Westmead Hospital — Westmead

Alabama

  • Uab Medicine — Birmingham

Arizona

  • Barrow Neurological Institute — Phoenix

Colorado

  • CenExel Rocky Mountain Clinical Research, LLC — Englewood

Florida

  • University of South Florida — Tampa

Illinois

  • Northwestern University — Chicago

Iowa

  • University of Iowa Hospitals and Clinics — Iowa City

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2024-09-02
Est. Completion 2028-09-24

Sponsor

Hoffmann-La Roche

758 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06667414

The ClinicalTrials.gov registry entry for NCT06667414 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06667414 reports 20 study locations spanning 18 distinct geographic areas — top geographies include California, New South Wales, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06667414 about?

NCT06667414 is a clinical study titled "Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers". For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and me...

What is the current status of trial NCT06667414?

This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-09-02. Estimated completion is 2028-09-24.

What conditions does trial NCT06667414 study?

This clinical trial studies the following conditions: Huntington Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT06667414?

This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06667414 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial